INKT - Multiplikator P/S MiNK

Tandha merek MiNK Therapeutics, Inc (INKT)

MiNK Therapeutics, Inc. (INKT) conducts immunotherapy research and development, completely ignoring economic cycles and GDP fluctuations. The primary growth driver is the clinical trials of the agenT-797 drug for the treatment of pneumonia and lung cancer. The company's P/S ratio reflects the current business valuation, with the 240.20 level serving as a critical benchmark. The early stage of allogeneic technologies results in high research expenses and a lack of profitability.

INKT (MiNK) riwayat Rasio rega marang pendapatan saka 14.11.2026 nganti 17.11.2026

MiNK (INKT) - rincian metrik lan laporan keuangan

- rega pasar lan target rega analis:
Analisis umum perusahaan:MiNK Therapeutics, INKT
Produk asil prodhuksi MiNK Therapeutics Inc.

A fundamental stress test of assets requires comparing the issuer's market value with its actual earnings. MiNK Therapeutics, Inc. (INKT) is developing a proprietary allogeneic platform using hybrid immune cells for oncology therapy. An analysis of the company's industry-average P/S ratio allows for an assessment of the capitalization-to-annual-revenue ratio, revealing the extent of priced-in growth expectations. A high multiple here signals confidence in innovation but increases the risk of a collapse if financial targets are not met.

Perusahaan pesaing

Kapitalisasi marang pendapatan ImmunityBio Corp IBRX|Immunocore Holdings - Kapitalisasi marang pendapatan|Multiplikator P/S Janux Corp JANX|RCUS - Rasio rega marang pendapatan|ZYME (zymeworks.com) - Rasio kapitalisasi marang pendapatan|Tango Therapeutics Corp (TNGX) - Rasio rega marang pendapatan|Rega marang dodolan Iovance (IOVA)|Kapitalisasi marang pendapatan IMTX|XNCR - Multiplikator rega marang pendapatan|Kapitalisasi marang pendapatan CMPX (Compass Bio)|Kapitalisasi marang volume dodolan REPL|Multiplikator P/S LYEL (Lyell Immunopharma, Inc.)|Rasio kapitalisasi pasar marang pendapatan IPHA|Pyxis - Multiplikator P/S|Rega marang dodolan Compugen|IO Biotech, Inc. (IOBT) - Rasio rega marang pendapatan|Sutro Biopharma, Inc. - Rasio kapitalisasi pasar marang pendapatan|HOWL (Werewolf) - Multiplikator P/S|Multiplikator P/S immixbio.com|Rasio rega marang pendapatan ALX Oncology Holdings (ALXO)|CUE - Rega marang dodolan|PDS Biotechnology Corporation - Kapitalisasi marang pendapatan|Sonnet BioTherapeutics (SONN) - Rega marang dodolan|MAIA - Rasio rega marang pendapatan|LIMN: Rasio rega marang pendapatan|LVTX: Multiplikator P/S|Rega marang dodolan NextCure, Inc. (NXTC)|LPTX (Leap Tx) - Multiplikator P/S|INTS (Intensity Therapeutics) - Kapitalisasi marang volume dodolan|Rasio rega marang pendapatan Sensei Bio (SNSE)|TOVX (Theriva Biologics) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan gritstonebio.com GRTS|Rasio kapitalisasi pasar marang pendapatan KA|NEXI - Rasio rega marang pendapatan|Turnstone Biologics Corp. - Kapitalisasi marang volume dodolan|VCNX: Multiplikator P/S|Rasio kapitalisasi marang pendapatan HARP